Showing results (151-160 of 188) with videos related to

Sort By:
Pageof 19
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2011
Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatmentYa-Ting Chen, John Wen-Cheng Chang, Hui-Ping Liu, et al.
Japanese Journal of Clinical Oncology|December 7, 2014
Cytoplasmic and nuclear parathyroid hormone-related proteins are opposing prognostic factors in patients with non-small-cell lung cancer who have undergone curative resectionChiao-En Wu, Chi-Wei Wang, Wen-Kuan Huang, et al.
Frontiers in Immunology|March 15, 2021
The Roles of Immunoregulatory Networks in Severe Drug HypersensitivityYun-Shiuan Olivia Hsu, Kun-Lin Lu, Yun Fu, et al.
BMC Cancer|March 25, 2021
A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failedChih-Hsi Scott Kuo, Pi-Hung Tung, Allen Chung-Cheng Huang, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|April 9, 2024
Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactionsHung-Chih Hsu, Wen-Hung Chung, Yung-Chang Lin, et al.
Asia-Pacific Journal of Clinical Oncology|May 19, 2011
Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trialTony S K Mok, Te-Chun Hsia, Chun-Ming Tsai, et al.
Asia-Pacific Journal of Clinical Oncology|May 19, 2011
Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and TaiwanMyung-Ju Ahn, Chun-Ming Tsai, Te-Chun Hsia, et al.
American Journal of Cancer Research|October 11, 2023
Generation and validation of a predictive model for estimating survival among patients with EGFR-mutant non-small cell lung cancerChien-Yu Lin, Yun-Tse Chou, Po-Lan Su, et al.
Clinical Medicine Insights. Oncology|July 8, 2025
Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort StudyI-Lin Tsai, Chien-Yu Lin, Po-Lan Su, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in TaiwanShiu-Feng Huang, Hui-Ping Liu, Ling-Hui Li, et al.
Pageof 19